➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
McKesson
Dow
Moodys

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,263,580


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,263,580 protect, and when does it expire?

Patent 8,263,580 protects SORILUX and is included in one NDA.

This patent has twenty-six patent family members in twelve countries.

Summary for Patent: 8,263,580
Title:Vitamin formulation
Abstract: A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
Inventor(s): Buchta; Richard (Rowville, AU), Houlden; Robert James (Rowville, AU), Ye; Rose (Rowville, AU), Larm; Maria Graziella (Rowville, AU), Loupenok; Leon (Rowville, AU)
Assignee: Stiefel Research Australia Pty Ltd (Rowville, AU)
Application Number:11/420,700
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,263,580

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS ⤷  Free Forever Trial
Mayne Pharma SORILUX calcipotriene AEROSOL, FOAM;TOPICAL 022563-001 Oct 6, 2010 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Colorcon
Johnson and Johnson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.